TICKERNOMICS Sign up
Last Update: 2023-12-23 05:57:45
Horizon Therapeutics Public Ltd Co ( HZNP ) https://www.horizontherapeutics.com
116.30USD
Sector:
Healthcare
Industry:
Drug Manufacturers-General
Country:
Ireland
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
HZNP
2.92%
SPY
30.72%
HZNP
71.86%
SPY
112.82%
HZNP
539.71%
SPY
201.04%
HZNP
1446.54%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
27206.71
29748.28
28.88
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
62.12
7.47
5.12
4.04
0.00
33.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
15.12
76.72
24.53
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.0828
5.06
5.82
1.02
Other Earnings and Cash Flow Stats:
Horizon Therapeutics Public Ltd Co ( HZNP ) Net Income TTM ($MM) is 444.29
Horizon Therapeutics Public Ltd Co ( HZNP ) Operating Income TTM ($MM) is 619.72
Horizon Therapeutics Public Ltd Co ( HZNP ) Owners' Earnings Annual ($MM) is 1134.32
Horizon Therapeutics Public Ltd Co ( HZNP ) Current Price to Owners' Earnings ratio is 23.60
Horizon Therapeutics Public Ltd Co ( HZNP ) EBITDA TTM ($MM) is 1045.04
Horizon Therapeutics Public Ltd Co ( HZNP ) EBITDA Margin is 24.53%
Capital Allocation:
Horizon Therapeutics Public Ltd Co ( HZNP ) has paid 0.00 dividends per share and bought back 1.449979 million shares in the past 12 months
Horizon Therapeutics Public Ltd Co ( HZNP ) has reduced its debt by 7.6819999999998 million USD in the last 12 months
Capital Structure:
Horizon Therapeutics Public Ltd Co ( HZNP ) Interest-bearing Debt ($MM) as of last quarter is 2573
Horizon Therapeutics Public Ltd Co ( HZNP ) Annual Working Capital Investments ($MM) are 283
Horizon Therapeutics Public Ltd Co ( HZNP ) Book Value ($MM) as of last quarter is 5310
Horizon Therapeutics Public Ltd Co ( HZNP ) Debt/Capital as of last quarter is 48%
Other Balance Sheet Stats:
Horizon Therapeutics Public Ltd Co ( HZNP ) has 2464 million in cash on hand as of last quarter
Horizon Therapeutics Public Ltd Co ( HZNP ) has 917 million of liabilities due within 12 months, and long term debt 2557 as of last quarter
Horizon Therapeutics Public Ltd Co ( HZNP ) has 233 common shares outstanding as of last quarter
Horizon Therapeutics Public Ltd Co ( HZNP ) has 0 million USD of preferred stock value
Academic Scores:
Horizon Therapeutics Public Ltd Co ( HZNP ) Altman Z-Score is 5.17 as of last quarter
Horizon Therapeutics Public Ltd Co ( HZNP ) Piotroski Score is 8.00 as of last quarter
Corporate Governance:
Horizon Therapeutics Public Ltd Co ( HZNP ) largest shareholder is Adage Capital Partners Gp LLC owning 2994606 shares at 348.27 ($MM) value
Daniel S. Goldman(an insider) Sold 0 shares of Horizon Therapeutics Public Ltd Co ( HZNP ) for the amount of $0.00 on 2023-01-31
1.18% of Horizon Therapeutics Public Ltd Co ( HZNP ) is held by insiders, and 100.85% is held by institutions
Horizon Therapeutics Public Ltd Co ( HZNP ) went public on 2011-07-28
Other Horizon Therapeutics Public Ltd Co ( HZNP ) financial metrics:
FCF:1097.97
Unlevered Free Cash Flow:1217.14
EPS:2.17
Operating Margin:15.12
Gross Profit Margin:76.72
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:9.57
Beta:1.02
Buffet's Owners Earnings:1134.32
Price to Owner's Earnings:23.60
About Horizon Therapeutics Public Ltd Co ( HZNP ) :
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.